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A Meeting of the Nutrition Society, hosted by the Scottish Section, was held at The Teacher Building, 14 St Enoch Square,
Glasgow on 5–6 April 2011
70th Anniversary Conference on ‘Nutrition and health:
from conception to adolescence’
Symposium I: Consequences of obesity and overweight during pregnancy
The consequences of obesity and excess weight gain in pregnancy
Jane E. Norman1* and Rebecca Reynolds1,2
1Tommy’s Centre for Maternal and Fetal Health, MRC Centre for Reproductive Health, Queen’s Medical Research
Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TY, UK
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The prevalence of obesity in pregnancy is rising exponentially; about 15–20% of pregnant
women now enter pregnancy with a BMI which would define them as obese. This paper
provides a review of the strong links between obesity and adverse pregnancy outcome which
operate across a range of pregnancy complications. For example, obesity is associated with an
increased risk of maternal mortality, gestational diabetes mellitus, thromboembolism, pre-
eclampsia and postpartum haemorrhage. Obesity also complicates operative delivery; it makes
operative delivery more difficult, increases complications and paradoxically increases the need
for operative delivery. The risk of the majority of these complications is amplified by excess
weight gain in pregnancy and increases in proportion to the degree of obesity, for example,
women with extreme obesity have OR of 7.89 for gestational diabetes and 3.84 for postpartum
haemorrhage compared to their lean counterparts. The consequences of maternal obesity do
not stop once the baby is born. Maternal obesity programmes a variety of long-term adverse
outcomes, including obesity in the offspring at adulthood. Such an effect is mediated at least
in part via high birthweight; a recent study has suggested that the odds of adult obesity are two-
fold greater in babies weighing more than 4 kg at birth. The mechanism by which obesity
causes adverse pregnancy outcome is uncertain. This paper reviews the emerging evidence that
hyperglycaemia and insulin resistance may both play a role: the links between hyperglycaemia
in pregnancy and both increased birthweight and insulin resistance have been demonstrated in
two large studies. Lastly, we discuss the nature and rationale for possible intervention strategies
in obese pregnant women.
Obesity in pregnancy: Pregnancy outcomes: Intervention strategies
Prevalence of obesity
The prevalence of obesity is rising worldwide. Scotland, in
particular, has one of the highest prevalences of obesity of
all Organisation for Economic Co-Operation and Devel-
opment countries(1), with a prevalence of 22% among men
and 24% among women in 2003. Given the above infor-
mation, it is not surprising that a significant proportion of
women enter pregnancy with a BMI which would define
them as obese. Published data from Scotland suggest that
18.9% of women in Glasgow have a BMI of 30 or more at
the time of pregnancy booking(2); these data concur with
our own data in Lothian where 16.3% of women had a
BMI of 30 or more at the time of booking in 2008(3). Data
from England suggest that the rise in rates of obesity in the
general population is widely paralleled in the population
of pregnant women(4,5) and although prevalences of obesity
in pregnant women remain 3–5% behind the general
Abbreviation: HAPO, hyperglycaemia and adverse pregnancy outcome.
*Corresponding author: Professor Jane Norman, email jane.norman@ed.ac.uk
Proceedings of the Nutrition Society (2011), 70, 450–456 doi:10.1017/S0029665111003077





















population, they are projected to be over 20% by the time
of writing in 2011.
The consequences of obesity in non pregnant individuals
have been extensively described. They include an in-
creased risk of type 2 diabetes (typical fold increase of 12),
hypertension (four-fold risk), myocardial infarction and
colon cancer (each a three-fold risk) angina, gall bladder
disease and ovarian cancer (two-fold risk) in addition to
conditions whose incidence is only modestly increased by
obesity such as stroke and osteoarthritis. A recent meta-
analysis has shown that for every increase in BMI of
5 kg/m2 there is a 10% increase in neoplastic mortality,
40% increase in vascular mortality and a greater than 50%
increase in diabetic, renal and hepatic mortality(6). In con-
trast, the impact of obesity on reproductive outcomes has
only recently been the subject of significant research(7).
In pregnancy in the UK, attention has been drawn to this
issue in the last two Confidential Enquiries on Maternal
Mortality(8,9). In the most recently reported triennium,
27% of women who died had a BMI of 30, a proportion in
excess of the proportion of obese women in the maternity
population. Thus, obese pregnant women appear to be at
increased risk of death during pregnancy. Regarding spe-
cific causes of death, overweight or obese pregnant women
were highly over-represented among those dying of throm-
boembolism (of whom 78% were overweight or obese)
and cardiac causes (of whom 61% were overweight
or obese)(8). Although disease pathophysiology clearly
plays a role, the previous triennium reported that lack of
basic equipment (e.g. lack of sphygmomanometer cuffs
of appropriate size to measure blood pressure in obese
pregnant women) and/or logistical issues (e.g. transport of
obese pregnant women) could also be a factor in the death
of some obese women(9).
In view of the increased mortality among obese pregnant
women, the report of the 2002–2005 triennium recom-
mended that ‘Preconception counselling and support, both
opportunistic and planned, should be provided for women
of childbearing age with pre-existing serious medical or
mental health conditions which may be aggravated by
pregnancy . . . . This includes obesity (BMI>30)(9).
While this recommendation is important and useful, it
is less clear how pre-conception advice can improve out-
come. Achieving a normal weight before embarking on
pregnancy is a counsel of perfection; if weight cannot be
lost the range of interventions which can improve outcome
among obese women remains limited(10).
Antenatal pregnancy complications increased
by obesity
Other than death, many adverse pregnancy outcomes are
increased by obesity. They include maternal haemorrhage,
maternal infection and longer hospital stay (Table 1)(11). In
parallel with these major adverse outcomes, the ‘minor’
complications of pregnancy (heartburn, chest infection
and symphysis pubis discomfort) are also increased in
obese pregnant women, with evidence of a dose-dependent
effect(3). Although ‘minor’ in terms of risk of mortality,
these events are not only distressing to the sufferer, but
have an adverse economic impact. In extreme obesity
(BMI>50) the risk of adverse outcomes increases further.
The United Kingdom Obstetric Surveillance system study
of extreme obesity identified that BMI>50 was associated
with increased adjusted OR of a range of adverse out-
comes, including gestational diabetes, thrombosis, pre-
eclampsia, postpartum haemorrhage and intensive care unit
admission (Table 2)(12).
Delivery complications
Delivery of an obese pregnant woman remains a challenge.
Obese women are more likely to require both caesarean sec-
tion and instrumental delivery(11) (Table 1), paradoxically
obese pregnant women are at an increased risk of the com-
plications associated with operative delivery. These risks
are further exaggerated in morbid obesity(12) (Table 2),
where operative delivery poses challenges to both the
anaesthetist and obstetrician. Given the high likelihood
of operative delivery, even where vaginal delivery is at-
tempted, the fact that ‘emergency’ caesarean section car-
ries greater risks than ‘elective’ caesarean section, and the
need for experienced members of staff if operative delivery
is needed, one could argue that women with morbid
obesity might be best delivered by elective caesarean sec-
tion. A prospective study of women with extreme obesity
delivered by elective caesarean section compared with
those in whom a vaginal delivery was planned showed no
evidence of reduced complications in the caesarean section
group, with the exception of a reduction in shoulder dys-
tocia(13). As the authors note, these data do not support
a policy of routine planned caesarean section for all
Table 1. Adverse pregnancy outcomes increased by obesity (data
from Heslehurst et al.(11))
Event OR (95% CI)
Maternal haemorrhage 1.24 (1.20, 1.28)
Maternal infection 3.35 (2.74, 4.06)
Longer hospital stay 2.84 (2.77, 2.91)
Caesarean section 2.00 (1.87, 2.15)
Instrumental delivery 1.17 (1.13, 1.21)
Table 2. Adverse pregnancy outcomes increased by extreme
obesity (data from Knight et al.(12))
Event Adjusted OR 95% CI
Antenatal and postpartum complications
Pre-eclampsia 4.46 2.42, 8.16
Induction of labour 1.97 1.53, 2.54
Postpartum haemorrhage 3.04 0.96, 9.67
Intensive care unit admission 3.86 1.41, 10.60
Gestational diabetes 7.89 3.94, 15.80
Thrombosis Infinity 0.75, infinity
Delivery complications
Shoulder dystocia 1.89 0.82, 4.34
Caesarean section 3.50 2.72, 4.51
Problems with epidural anaesthetic 3.54 1.49, 8.42
Problems with spinal anaesthetic 9.10 2.02, 41.00





















morbidly obese women. In the Edinburgh metabolic
antenatal clinic over the last few years, we have made a
decision for delivery by elective caesarian on an individual
patient basis after multidisciplinary discussion and careful
consultation with the pregnant woman on a number of
occasions.
Immediate effects of maternal obesity on the baby
The adverse effects of obesity in pregnancy are not con-
fined to problems for the mother; the baby also is at risk
from events arising in pregnancy. These events range from
miscarriage and stillbirth, through fetal abnormality to
macrosomia (Table 3)(11,14,15). A meta-analysis in the
Lancet recently identified overweight and obesity as the
single biggest modifiable factor in stillbirth in resource-
rich countries(16). Additionally, the increased risk of a
variety of maternal pregnancy complications results in an
increased risk of induced preterm birth with a relative risk
1.30 (95% CI 1.23, 1.37)(17).
Weight gain during pregnancy
Given the known adverse effects of obesity in pregnancy,
it is not surprising that these effects are mimicked or am-
plified by excess weight gain in pregnancy. Excess gesta-
tional weight gain is associated with increased mean
birthweight and an increased incidence of babies being
large for gestational age(18). Conversely, inadequate gesta-
tional weight gain is associated with low birthweight and
an increased incidence of babies being small for gesta-
tional age. For the mother, increasing evidence suggests
that high gestational weight gain results in increased
maternal obesity, as well as higher blood pressure, later in
life(19). Although there is clear evidence that ‘too much’
and ‘too little’ weight gain in pregnancy is not good, there
are limited data to properly inform the ranges of appro-
priate weight gain. Notwithstanding, the Institute of Med-
icine in the USA recently issued guidelines on weight gain,
suggesting for the first time that those with a high BMI at
the onset of pregnancy should limit weight gain, compared
with those with a normal or low BMI at booking(20). The
Institute of Medicine recommendations are shown in
Table 4. Importantly, there is as yet insufficient evidence
to suggest that women with a very high BMI (BMI ‡ 40)
should lose weight in pregnancy; cohort studies suggest
that although such a strategy can minimise the risk of
macrosomia, caesarean section and pre-eclampsia, it does
so at the expense of an increased incidence of babies that
are small for gestational age(21).
Programming of adverse pregnancy outcome
In addition to the immediate adverse consequences of
maternal obesity and/or excess weight gain in pregnancy,
growing evidence suggests that maternal obesity can ‘pro-
gramme’ the baby for disease in future life(22). For exam-
ple, Reichman and Nepomnyaschy showed that maternal
obesity increases offspring asthma, with an OR of 1.52
(95% CI 1.18,1.93)(23). Others have shown a possible link
between maternal obesity and adverse neurodevelopmental
outcomes, including cognitive problems and attention-
deficit disorders in the baby(24). However, the most widely
investigated programming effect of maternal obesity is on
offspring obesity. There are now several observational
studies supporting an association between maternal obesity
and increased risk of obesity in the offspring as neonates,
in childhood and in adolescence (see Drake and Reynolds
for review(22)). We have recently shown that offspring fat
mass and weight circumference in adulthood are also
positively related to maternal BMI during pregnancy(25)
independently of adult obesity lifestyle factors. In addition
to these studies directly correlating offspring obesity in
adulthood with maternal BMI, further studies using the
surrogate of offspring birthweight support a link between
maternal obesity and offspring obesity. As described
earlier, maternal obesity is associated with high offspring
birthweight. Linking birthweight and adult obesity, both
the Nurses Health Studies (women) and the Health Pro-
fessionals Follow-up study (men), large studies of about
163 000 and 22 000 sample size, respectively, showed a
J-shaped association (in other words, a positive association
at both ends of the curve) between birthweight and adult
obesity(26,27). A systematic review by Parsons also demon-
strated positive associations between birthweight and adult
obesity, regardless of the method of obesity measurement
(BMI, weight, skinfold thickness etc.)(28). This positive
association between high birthweight (>4000 g) and adult
obesity was confirmed again in the most recent systematic
review with OR (95% CI) of adult obesity of 2.07 (1.91–
2.24): interestingly this review suggested that the associa-
tion between low birthweight and adult obesity disappeared
after studies with selection bias were excluded(29).
The results of these epidemiological studies are recapi-
tulated in animal studies, where maternal and offspring
food intake can be tightly regulated, with environmen-
tal parameters carefully controlled between the groups.
Table 3. Adverse outcomes for the baby – data from Chu et al.,
Heslehurst et al. and Metwally et al.(11,14,15)
Event OR (95% CI)
Miscarriage 1.67 (1.25, 2.25)
Stillbirth 2.07 (1.59, 2.74)
Shoulder dystocia 1.04 (0.97, 1.12)
Neonatal intensive care unit admission 1.35 (1.22, 1.49)
Fetal abnormality Increased
Macrosomia Increased
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Bayol et al.(30) determined perirenal fat mass in rats
exposed to a ‘junk food’ or a ‘normal’ diet, all on the
background of either maternal junk food intake during
pregnancy or normal diet during pregnancy. Not surpris-
ingly, rats exposed to a junk-food diet both post-weaning
and in utero had the greatest perirenal fat mass, and one
that was substantially greater than rats never exposed to
junk food. Rats exposed to junk food post-weaning, but not
in utero, also displayed greater perirenal fat mass com-
pared to normal-diet controls, albeit less pronounced than
those exposed to junk food in utero. Of perhaps most sur-
prise, however, rats exposed to junk food in utero, but then
transferred to chow diet post-natally, also showed
increased perirenal fat mass compared to controls (these
differences reaching statistical significance in males but
not females), indicating that the in utero effects of ma-
ternal obesity have consequences long beyond pregnancy.
Although such studies cannot be replicated in human sub-
jects, it appears likely that similar effects do occur
although it is difficult to disentangle post-natal lifestyle
influences. Catalano has postulated a scenario whereby
maternal obesity during pregnancy begets fetal and neo-
natal obesity(31). There is a potential for neonatal obesity to
be modified in childhood by diet and exercise, but if it is
not, it becomes childhood obesity (often accompanied by a
decrease in insulin sensitivity), again with the potential
modifiers of diet and exercise(32), but if unmodified it
becomes adult obesity (often accompanied by type 2 dia-
betes), which in women who become pregnant again
exposes the fetus to obesity in utero and an abnormal
metabolic environment(31).
What mechanisms link obesity and adverse
pregnancy outcome?
An understanding of mechanisms is required in order to
devise therapies to treat the links between obesity and
adverse pregnancy outcome. Several mechanisms have
been postulated, but the ones backed by most evidence,
and which will be discussed here, are hyperglycaemia and
insulin resistance.
Impaired glucose tolerance
The links between diabetes and obesity are well recog-
nised. The positive association between high glucose and
high BMI remains, even below a ‘cut off’ level of glucose
which would qualify for a diagnosis of diabetes. For
example, Abbasi et al. showed a continuous positive associ-
ation (r 0.465, P<0.01) between BMI and plasma glucose
concentration(33), in a study of 300 healthy men. These
results have been recapitulated in pregnancy, with maternal
glucose concentrations of <99 mg/dl (5.5 mmol/l), 99–
130 mg/dl and >130 mg/dl (7.2 mmol/l) in women in the
Camden health study segregating women into those with a
mean pre-gravid BMI of 23.2, 23.9 and 25.0, respectively
(P<0.001)(34). This study also confirmed the veracity of
the Pedersen hypothesis, that is, high maternal blood glu-
cose results in increased nutrient transfer to the fetus and
hence increased fetal growth(35), in that blood glucose
concentrations also correlated with increasing risk of
having a large-for-gestational-age baby: taking glucose of
<99 mg/dl (5.5 mmol/l) as a referent, those with a medium
(99–130 mg/dl) and high (>130) blood glucose had odds of
a large-for-gestational-age baby of 1.4 and 3.59, respec-
tively. Although Pedersen defined his hypothesis to explain
macrosomia among babies of diabetic women, a similar
paradigm appears to operate in women with a modestly
elevated blood glucose but below the threshold for diag-
nosis of gestational diabetes.
In the Camden study, blood glucose segregated with
rates of caesarean section as well as macrosomia. With
glucose of <99 mg/dl as referent, medium and highest
blood glucose levels had odds of caesarean section of 1.31
and 2.64, respectively.
Although the Camden health study is large, with data on
over 1000 women, it is dwarfed by the hyperglycaemia and
adverse pregnancy outcome (HAPO) study which shows
similar effects(36). In HAPO, over 25 000 women under-
went a 75 g glucose tolerance test in the late second
or early third gestation. Those with gestational diabetes
(fasting plasma glucose above 5.8 mmol/l of 2-h plasma
glucose above 11.1 mmol/l) were identified and treated
appropriately. The results of the glucose tolerance test
remained concealed in the 23 000 women who did not have
gestational diabetes. At the end of the study, the OR of
adverse pregnancy outcomes were correlated against blood
glucose profile. The prespecified primary outcomes were:
birthweight above the 90th centile for gestational age, pri-
mary caesarean delivery, clinically diagnosed neonatal
hypoglycaemia and cord-blood C-peptide level above the
90th centile. HAPO showed a direct relationship between
each of birth weight above the 90th centile and primary
caesarean section frequency, and blood glucose, with those
in the highest blood glucose band having a greater pro-
portion of women with babies >90th centile in weight and
being delivered by primary caesarean section. There was
also an increase in adverse outcomes of premature deliv-
ery, shoulder dystocia, requirement for neonatal intensive
care, hyperbilirubinaemia and pre-eclampsia (Table 5).
Thus, HAPO confirms the link between high blood glucose
levels (even those not normally considered to qualify for
gestational diabetes) and adverse pregnancy outcome,
including high birthweight. Other studies have shown that
this positive correlation between maternal blood glucose
and offspring BMI may persist into early childhood(37)
although the association may not be apparent in very
young children(38). That association between maternal
glucose and adverse pregnancy outcome including high
Table 5. Secondary outcomes from the HAPO study(36)
Outcome
OR of adverse outcome
with increase in
2 h glucose of 1 SD
Premature delivery (<37 weeks) 1.16 (1.10–1.23)
Shoulder dystocia or birth injury 1.22 (1.09–1.37)
Intensive neonatal care 1.09 (1.03–1.14)
Hyperbilirubinemia 1.08 (1.02–1.13)
Pre-eclampsia 1.28 (1.20–1.37)





















birthweight is causal (i.e. that high blood glucose causes
adverse pregnancy outcome) rather than a mere association
is evidenced by the Australian Carbohydrate Intolerance
Study in pregnant women study, in which women with
modestly impaired glucose tolerance (fasting glucose
<7.8 mmol/l and 2 h post 75 g oral glucose load of 7.8–
11.0 mmol) were randomised routine care or to diet and
insulin(39). Although the risk of the composite adverse
perinatal outcome was low in both groups 4 v. 1%,
respectively, those randomised to diet and insulin had a
lower incidence of the adverse outcome compared with
those in the routine care group (relative risk 0.33, 95% CI
0.14, 0.75). Thus, there is good evidence that not only is
modestly elevated blood glucose causal in the aetiology of
adverse pregnancy outcome, but also that treatment (with
diet and insulin) can ameliorate this causal link. Given that
obese pregnant women have modestly elevated blood glu-
cose compared to their lean counterparts, and have
increased incidence of the adverse pregnancy outcomes
(larger babies and caesarean section) compared to lean
pregnant women, it is likely that elevated blood glucose
concentrations mediate (at least in part) the effects of
obesity on adverse pregnancy outcome.
Longer term, there is emerging evidence that maternal
blood glucose concentration programmes the offspring for
later-life obesity. Dabelea’s seminal study showing a
greater incidence of obesity and diabetes in Pima Indians
born after their mothers developed gestational diabetes,
compared to their siblings born beforehand but no differ-
ence in the incidence of either diabetes or obesity after
paternal development of diabetes(40) provides important
evidence of the programming effect of being exposed to
high glucose levels in utero. This study has recently been
confirmed in a study of 280 000 Swedish men, where the
mean BMI of men aged 18 was 0.94 kg/m2 (95% CI 0.35,
1.52) greater in those who were born after compared to
their siblings born before their mothers developed gesta-
tional diabetes, after adjustment for a variety of con-
founding factors(41).
Insulin resistance
The evidence for elevated maternal glucose mediating
adverse pregnancy outcome is strong. In contrast, there is
less evidence for the links between insulin resistance and
adverse pregnancy outcome. However, obese pregnant
women are insulin resistant compared to their lean preg-
nant counterparts(42,43). Challier et al. assessed insulin
sensitivity from fasting glucose and insulin measurements
using the Homeostasis Model Assessment and found mean
Homoeostasis Model Assessment to be 4.3 (SD 0.5) in a
group of obese pregnant women, compared with 1.2
(SD 0.3) in lean pregnant women (P<0.001) (i.e. increased
insulin resistance in the obese). Ramsay et al. showed
median (interquartile range) insulin levels to be 14.2
(11.3–27) and 6.15 (4.47–9.5) in obese v. lean pregnant
women (P<0.0001), respectively, again suggesting
increased insulin resistance in obese. To our knowledge, no
studies have attempted to correlate insulin resistance with
adverse pregnancy outcome. However, insulin resistance is
a common finding in women with polycystic ovary syn-
drome (defined as two out of the three symptoms of oligo-
or amenorrhoea, excess androgen activity and polycystic
ovaries demonstrable on ultrasound examination): a meta-
analysis of outcomes in pregnant women with a history of
polycystic ovary syndrome showed an increased incidence
of a variety of adverse pregnancy outcome including
macrosomia (OR 1.13, 95% CI 0.73, 1.75) and caesarean
section (OR 1.56, 95% 1.20, 2.02)(44) (Table 6). Thus,
there is circumstantial evidence that insulin resistance may
also link obesity to adverse pregnancy outcome.
Interventions
Understanding the links between obesity and adverse
pregnancy outcome can inform effective therapeutic inter-
ventions. In non-pregnant individuals, diet and exercise are
advocated to improve health. In pregnancy, there is limited
evidence for the efficacy of diet and exercise(45) although
several trials are underway to test these interventions (e.g.
UPBEAT ISRCTN: 89971375).
Given the known links between obesity, elevated blood
glucose, insulin resistance and adverse pregnancy outcome,
we believe that metformin may be an appropriate therapy
for obese pregnant women. Metformin is a biguanide
which increases glucose uptake in the liver and skeletal
muscle, and decreases hepatic glucose production, likely
via increased AMP-activated protein kinase(46). Its use is
endorsed as the first-line treatment for gestational diabe-
tes(47)based on the results of the metformin v. insulin for
the treatment of gestational diabetes study(48). In the met-
formin v. insulin for the treatment of gestational diabetes
study, 751 women with gestational diabetes, diagnosed
between 20 and 33 weeks gestation, were randomised
either to metformin, with or without insulin if necessary, or
to insulin directly. The composite primary outcome was
neonatal hypoglycaemia or respiratory distress or need for
phototherapy or birth trauma or 5 min Apgar score less
than 7 or prematurity. The incidence of the primary out-
come was similar in both groups (32.0% in the metformin
group and 32.2% in the insulin group), relative risk 0.99,
95% CI 0.80,1.23. There was no difference in birthweight.
Just under 50% of the metformin group needed to take
insulin in addition to metformin, but the remainder did
not. Maternal weight gain (from enrolment to 36 weeks
Table 6. Adverse pregnancy outcomes in women with polycystic
ovary syndrome(44)
Outcome OR (95% CI)
Gestational diabetes 2.94 (1.70, 5.08)
Pregnancy-induced hypertension 3.67 (1.98, 6.81)
Caesarean section 1.56 (1.20, 2.02)
Preterm delivery 1.75 (1.16, 2.62)
Macrosomia 1.13 (0.73, 1.75)
NICU admission 2.31 (1.25, 4.26)
Perinatal mortality 3.07 (1.03, 9.21)
NICU, neonatal intensive care unit.





















gestation) was, however, lower in the metformin group: 0.4
(SD 2.9) kg v. 2.0 (SD 3.3) kg, P<0.001.
We hypothesise that metformin, in reducing modestly
elevated blood glucose and improving insulin resistance,
might reduce adverse outcome in obese pregnant women.
We are testing this hypothesis in the EMPOWaR study
(ISRCTN 1279843), funded by the Medical Research
Council, and managed by the Efficacy and Mechanisms
Evaluation board on behalf of the National Institute for
Health Research. In EMPOWaR, 400 obese pregnant
women will be randomised to metformin or placebo from
12 to 16 weeks of pregnancy until delivery. The primary
outcome is birthweight centile, but we will also look at the
effect of metformin on vascular function, glucose disposal
and baby fat mass. We hope that metformin may reduce
mean birthweight (i.e. reduce excess birthweight centile)
without increasing the risk of intrauterine growth
retardation.
Summary
The ideal management of maternal obesity is prevention,
but it seems unlikely that the increasing prevalence of
obesity in pregnancy is going to change soon. The links
between maternal obesity and adverse outcome are strong,
and operate across a range of pregnancy complications.
Further research is urgently needed to understand these
links, in order to be able to develop therapies, and improve
pregnancy outcome in this increasingly common condition.
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